Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early January 2025 and randomization of the last patient expected within the first half of 2025Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lan ...